Month: October 2014
Incorporation of the Time-dependent Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on Oral Propranolol Pharmacokinetics
Rationale for Design of Pharsight Modeling Language (PML)
Modeling the Binding Kinetics of Antibody, Antigen, and FcyRs
Certara Consultants to Discuss PK/PD Modeling Advances and ISoP Standards at ACoP5
Certara consultants will present a total of five seminars and five posters at ACoP5 being held from Oct. 12-15 in Las Vegas, Nev. ST. LOUIS, MO – Oct. 8, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that its Simcyp and Pharsight consultants will present a total of … Continued
Oseltamivir Use in an Influenza Outbreak: Linking Pharmacology to Pharmacoeconomics
Estimating Health Outcomes of Antiviral Use in Influenza Outbreaks by Linking PK/PD and Epidemiology via a Transmission Dynamic Model: A Novel Approach
The Rise of Systems Pharmacology in Drug Discovery and Development
Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics
In drug development, considerable efforts are made to extrapolate from in vitro and preclinical findings to predict human drug disposition by using in vitro-in vivo extrapolation (IVIVE) approaches. Use of IVIVE strategies linked with physiologically based pharmacokinetic (PBPK) modeling is widespread, and regulatory agencies are accepting and occasionally requesting model analysis to support licensing submissions. … Continued
Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis
Our objective was to compare the time course of bone mineral density (BMD) changes at the lumbar spine (LS) and total hip (TH) in postmenopausal women during treatment with denosumab, bisphosphonates, selective estrogen receptor modulators, PTH, or calcitonin. Data were extracted from 142 randomized controlled trials for prevention or treatment of postmenopausal osteoporosis representing over … Continued
